453 related articles for article (PubMed ID: 8514251)
1. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis.
Rudolph G; Endele R; Senn M; Stiehl A
Hepatology; 1993 Jun; 17(6):1028-32. PubMed ID: 8514251
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of ursodeoxycholic acid and chenodeoxycholic acid on bile acid kinetics and biliary lipid secretion in humans. Evidence for different modes of action on bile acid synthesis.
Nilsell K; Angelin B; Leijd B; Einarsson K
Gastroenterology; 1983 Dec; 85(6):1248-56. PubMed ID: 6628924
[TBL] [Abstract][Full Text] [Related]
3. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
4. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease.
Beuers U; Spengler U; Zwiebel FM; Pauletzki J; Fischer S; Paumgartner G
Hepatology; 1992 Apr; 15(4):603-8. PubMed ID: 1551637
[TBL] [Abstract][Full Text] [Related]
5. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
Wolf JM; Rybicki LA; Lashner BA
Aliment Pharmacol Ther; 2005 Nov; 22(9):783-8. PubMed ID: 16225486
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.
Beuers U; Spengler U; Kruis W; Aydemir U; Wiebecke B; Heldwein W; Weinzierl M; Pape GR; Sauerbruch T; Paumgartner G
Hepatology; 1992 Sep; 16(3):707-14. PubMed ID: 1505913
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous determination of pool sizes and fractional turnover rates, of deoxycholic acid, cholic acid and chenodeoxycholic acid in man by isotope dilution with 2H and 13C labels and serum sampling.
Stellaard F; Sackmann M; Berr F; Paumgartner G
Biomed Environ Mass Spectrom; 1987 Nov; 14(11):609-11. PubMed ID: 2962664
[TBL] [Abstract][Full Text] [Related]
8. Changes in biliary lipid secretion and cholic acid kinetics induced by diet, diet plus simvastatin and diet plus ursodeoxycholic acid in obese subjects.
Mazzella G; Cipolla A; Villanova N; Polimeni C; Sipahi A; Parini P; Fusaroli P; Festi D; Roda E
Ital J Gastroenterol; 1995; 27(8):441-5. PubMed ID: 8775472
[TBL] [Abstract][Full Text] [Related]
9. Differences in the effects of chenodeoxycholic and ursodeoxycholic acid on biliary lipid secretion and bile acid synthesis in patients with gallstones.
von Bergmann K; Epple-Gutsfeld M; Leiss O
Gastroenterology; 1984 Jul; 87(1):136-43. PubMed ID: 6724256
[TBL] [Abstract][Full Text] [Related]
10. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration.
Crosignani A; Podda M; Battezzati PM; Bertolini E; Zuin M; Watson D; Setchell KD
Hepatology; 1991 Dec; 14(6):1000-7. PubMed ID: 1959845
[TBL] [Abstract][Full Text] [Related]
11. Temporary resolution of obstructive jaundice during ursodeoxycholic acid therapy in a patient with primary sclerosing cholangitis and a dominant biliary stricture.
Fracchia M; Soubrane O; Houssin D; Galatola G
Ital J Gastroenterol; 1995; 27(8):430-5. PubMed ID: 8775469
[TBL] [Abstract][Full Text] [Related]
12. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
13. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
[TBL] [Abstract][Full Text] [Related]
14. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.
Rudolph G; Kloeters-Plachky P; Rost D; Stiehl A
Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):487-91. PubMed ID: 17489059
[TBL] [Abstract][Full Text] [Related]
15. Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis.
Mazzella G; Parini P; Bazzoli F; Villanova N; Festi D; Aldini R; Roda A; Cipolla A; Polimeni C; Tonelli D
Dig Dis Sci; 1993 May; 38(5):896-902. PubMed ID: 8482188
[TBL] [Abstract][Full Text] [Related]
16. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study.
Trottier J; Białek A; Caron P; Straka RJ; Heathcote J; Milkiewicz P; Barbier O
Dig Liver Dis; 2012 Apr; 44(4):303-10. PubMed ID: 22169272
[TBL] [Abstract][Full Text] [Related]
18. [Bile acids in liver diseases--current indications].
Stiehl A
Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
[TBL] [Abstract][Full Text] [Related]
19. Pool size, synthesis, and turnover of sulfated and nonsulfated cholic acid and chenodeoxycholic acid in patients with cirrhosis of the liver.
Stiehl A; Ast E; Czygan P; Fröhling W; Raedsch R; Kommerell B
Gastroenterology; 1978 Mar; 74(3):572-7. PubMed ID: 631488
[TBL] [Abstract][Full Text] [Related]
20. Effect of litholytic bile acids on cholesterol absorption in gallstone patients.
LaRusso NF; Thistle JL
Gastroenterology; 1983 Feb; 84(2):265-71. PubMed ID: 6848406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
